All In Biotech

Drug Trial Radar · NCT03759379

HELIOS-A: A Study of Vutrisiran (ALN-TTRSC02) in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)

HELIOS-A: A Phase 3 Global, Randomized, Open-label Study to Evaluate the Efficacy and Safety of ALN-TTRSC02 in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)

Last checked: Nov 19, 2026Latest source record: Jan 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 164 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

164

Actual

Start

Feb 14, 2019

Primary completion

Nov 10, 2020

Study completion Nov 5, 2025

Sponsor

Lead sponsor
Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
Sponsor type
Industry
First posted
Nov 30, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of vutrisiran (ALN-TTRSC02) in participants with hereditary transthyretin amyloidosis (hATTR amyloidosis). Participants will receive vutrisiran subcutaneous (SC) injection once every 3 months (q3M) or the reference comparator patisiran intravenous (IV) injection once every 3 weeks (q3w) during the 18 month Treatment Period. This study will use the placebo arm of the APOLLO study (NCT01960348) as an external comparator for the primary and most other efficacy endpoints during the 18 Month Treatment Period. Following the 18 Month Treatment Period, all participants will be randomized to receive vutrisiran 50 mg SC injection once every 6 months (q6M) or vutrisiran 25 mg q3M in the Randomized Treatment Extension (RTE) Period. Upon implementation of Amendment 6, participants receiving vutrisiran SC 50 mg q6M will transition to vutrisiran SC 25 mg q3M at their next scheduled dosing.

Conditions

  • Amyloidosis, Hereditary
  • Transthyretin Amyloidosis

Interventions

  • PatisiranDrug

    Patisiran will be administered by IV infusion.

  • VutrisiranDrug

    Vutrisiran will be administered by SC injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in the Modified Neurologic Impairment Score +7 (mNIS+7) at Month 9 Between the Vutrisiran Group (HELIOS-A) and the External Placebo Comparator Group [APOLLO (NCT01960348)]Time frame: Baseline, Month 9

Locations

64 sites in 22 countries. Site status is shown where the registry gives one.

  • Clinical Trial Site

    La Mesa, California

  • Clinical Trial Site

    Aurora, Colorado

  • Clinical Trial Site

    Jacksonville, Florida

  • Clinical Trial Site

    Chicago, Illinois

  • Clinical Trial Site

    Fairway, Kansas

  • Clinical Trial Site

    Baltimore, Maryland

  • Clinical Trial Site

    Boston, Massachusetts

  • Clinical Trial Site

    Rochester, Minnesota

  • Clinical Trial Site

    St Louis, Missouri

  • Clinical Trial Site

    New York, New York

  • Clinical Trial Site

    Chapel Hill, North Carolina

  • Clinical Trial Site

    Columbus, Ohio

  • Clinical Trial Site

    Portland, Oregon

  • Clinical Trial Site

    Philadelphia, Pennsylvania

  • Clinical Trial Site

    Dallas, Texas

  • Clinical Trial Site

    Buenos Aires, Argentina

  • Clinical Trial Site

    Northmead, New South Wales, Australia

  • Clinical Trial Site

    Brisbane, Queensland, Australia

  • Clinical Trial Site

    Melbourne, Victoria, Australia

  • Clinical Trial Site

    Brussels, Belgium

  • Clinical Trial Site

    Leuven, Belgium

  • Clinical Trial Site

    Rio de Janeiro, Brazil

  • Clinical Trial Site

    Sofia, Bulgaria

  • Clinical Trial Site

    Montreal, Canada

  • Clinical Trial Site

    Vancouver, Canada

  • Clinical Trial Site

    Nicosia, Cyprus

  • Clinical Trial Site

    Bordeaux, France

  • Clinical Trial Site

    Créteil, France

  • Clinical Trial Site

    Le Kremlin-Bicêtre, France

  • Clinical Trial Site

    Lille, France

  • Clinical Trial Site

    Marseille, France

  • Clinical Trial Site

    Nantes, France

  • Clinical Trial Site

    Heidelberg, Germany

  • Clinical Trial Site

    Mainz, Germany

  • Clinical Trial Site

    Münster, Germany

  • Clinical Trial Site

    Athens, Greece

  • Clinical Trial Site

    Messina, Italy

  • Clinical Trial Site

    Milan, Italy

  • Clinical Trial Site

    Pavia, Italy

  • Clinical Trial Site

    Rome, Italy

Showing 40 of 64 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.